CI vs ICCC · P/E 2.4, rev $274.90B vs rev $26.5M
Cigna Corp (CI) versus ImmuCell Corporation (ICCC) — a side-by-side from cached financials, not a winner call.
Cigna Corp (CI) is a healthcare plans company listed on US.
ImmuCell Corporation (ICCC) is a biotechnology company listed on US.
Latest reported CI revenue for 2025-12-31 was $274.90B. Net income was $5.96B. Revenue was up 11.2% from 2024-12-31 to 2025-12-31. CI currently screens at market cap $71.62B and trailing P/E 2.4.
Latest reported ICCC revenue for 2024-12-31 was $26.5M. Net income was -$2.2M. Revenue was up 51.6% from 2023-12-31 to 2024-12-31. ICCC currently screens at market cap $58.9M.
CI currently screens at market cap $71.62B and trailing P/E 2.4. ICCC currently screens at market cap $58.9M.
Not investment advice. Open the CI and ICCC stock pages for the full models.
Not investment advice.